Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

36 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A multi-center phase II trial evaluating the efficacy of palbociclib in combination with carboplatin for the treatment of unresectable recurrent or metastatic head and neck squamous cell carcinoma.
Swiecicki PL, Durm G, Bellile E, Bhangale A, Brenner JC, Worden FP. Swiecicki PL, et al. Among authors: durm g. Invest New Drugs. 2020 Oct;38(5):1550-1558. doi: 10.1007/s10637-020-00898-2. Epub 2020 Jan 24. Invest New Drugs. 2020. PMID: 31981071 Free PMC article. Clinical Trial.
CX-072 (pacmilimab), a Probody ® PD-L1 inhibitor, in advanced or recurrent solid tumors (PROCLAIM-CX-072): an open-label dose-finding and first-in-human study.
Naing A, Thistlethwaite F, De Vries EGE, Eskens FALM, Uboha N, Ott PA, LoRusso P, Garcia-Corbacho J, Boni V, Bendell J, Autio KA, Randhawa M, Durm G, Gil-Martin M, Stroh M, Hannah AL, Arkenau HT, Spira A. Naing A, et al. Among authors: durm g. J Immunother Cancer. 2021 Jul;9(7):e002447. doi: 10.1136/jitc-2021-002447. J Immunother Cancer. 2021. PMID: 34301809 Free PMC article.
A phase 2 trial of chemotherapy plus pembrolizumab in patients with advanced non-small cell lung cancer previously treated with a PD-1 or PD-L1 inhibitor: Big Ten Cancer Research Consortium BTCRC-LUN15-029.
Salous T, Shukla NA, Althouse SK, Perkins SM, Furqan M, Leal T, Traynor AM, Feldman LE, Hanna NH, Durm GA. Salous T, et al. Cancer. 2023 Jan 15;129(2):264-271. doi: 10.1002/cncr.34565. Epub 2022 Nov 24. Cancer. 2023. PMID: 36420773 Free article. Clinical Trial.
[No title available]
[No authors listed] [No authors listed] PMID: 37784419
Radioluminescent nanoparticles for radiation-controlled release of drugs.
Misra R, Sarkar K, Lee J, Pizzuti VJ, Lee DS, Currie MP, Torregrosa-Allen SE, Long DE, Durm GA, Langer MP, Elzey BD, Won YY. Misra R, et al. J Control Release. 2019 Jun 10;303:237-252. doi: 10.1016/j.jconrel.2019.04.033. Epub 2019 Apr 23. J Control Release. 2019. PMID: 31026550 Free article.
36 results